Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 585

1.

PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.

Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G.

Am J Surg Pathol. 2018 Jun 12. doi: 10.1097/PAS.0000000000001105. [Epub ahead of print]

PMID:
29901568
2.

Late Development of FcεRγneg Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients.

Muccio L, Falco M, Bertaina A, Locatelli F, Frassoni F, Sivori S, Moretta L, Moretta A, Della Chiesa M.

Front Immunol. 2018 May 15;9:1050. doi: 10.3389/fimmu.2018.01050. eCollection 2018.

3.

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.

Pistoia V, Tumino N, Vacca P, Veneziani I, Moretta A, Locatelli F, Moretta L.

Front Immunol. 2018 May 7;9:984. doi: 10.3389/fimmu.2018.00984. eCollection 2018. Review.

4.

NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.

Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L.

Trends Immunol. 2018 Jul;39(7):577-590. doi: 10.1016/j.it.2018.04.009. Epub 2018 May 21. Review.

PMID:
29793748
5.

NK cell editing mediates Epithelial to Mesenchymal Transition via phenotypic and proteomic changes in melanoma cell lines.

Huergo Zapico L, Parodi M, Cantoni C, Lavarello C, Fernández-Martínez JL, Petretto A, DeAndrés-Galiana EJ, Balsamo M, López-Soto A, Pietra G, Bugatti M, Munari E, Marconi M, Mingari MC, Vermi W, Moretta L, Gonzalez S, Vitale M.

Cancer Res. 2018 May 11. pii: canres.1891.2017. doi: 10.1158/0008-5472.CAN-17-1891. [Epub ahead of print]

PMID:
29752261
6.

PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.

Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, Moretta F, Mingari MC, Pegoraro MC, Inno A, Paiano S, Terzi A, Cavazza A, Rossi G, Mariotti FR, Vacca P, Moretta L, Bogina G.

J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543-4. doi: 10.1016/j.jtho.2018.04.017. [Epub ahead of print]

7.

Alessandro Moretta 1953-2018.

Moretta L, Mantovani A.

Nat Immunol. 2018 Apr;19(4):315. doi: 10.1038/s41590-018-0075-5. No abstract available.

PMID:
29563619
8.

PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.

Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G.

Oncotarget. 2017 Oct 4;8(52):90123-90131. doi: 10.18632/oncotarget.21485. eCollection 2017 Oct 27.

9.

Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.

Cifaldi L, Locatelli F, Marasco E, Moretta L, Pistoia V.

Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10. Review.

PMID:
29133133
10.

Guidelines for the use of flow cytometry and cell sorting in immunological studies.

Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Dreher A, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lugli E, Maecker HT, Martrus G, Matarese G, Maueröder C, McGrath M, McInnes I, Mei HE, Melchers F, Melzer S, Mielenz D, Mills K, Mirrer D, Mjösberg J, Moore J, Moran B, Moretta A, Moretta L, Mosmann TR, Müller S, Müller W, Münz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudörfl C, Nolan J, Nourshargh S, O'Connor JE, Ouyang W, Oxenius A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRDJ, Rajwa B, Rebhahn JA, Recktenwald D, Remmerswaal EBM, Rezvani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruckert B, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sawitzki B, Scheffold A, Schiemann M, Schildberg F, Schimisky E, Schmid SA, Schmitt S, Schober K, Schüler T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon AK, Spidlen J, Stall AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tornack J, Traggiai E, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Volkmann K, Waisman A, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiedemann A, Wienands J, Willimsky G, Wing J, Wurst P, Yu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J.

Eur J Immunol. 2017 Oct;47(10):1584-1797. doi: 10.1002/eji.201646632. No abstract available.

PMID:
29023707
11.

Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up-regulation.

Del Zotto G, Antonini F, Azzari I, Ortolani C, Tripodi G, Giacopelli F, Cappato S, Moretta L, Ravazzolo R, Bocciardi R.

Cytometry B Clin Cytom. 2017 Oct 6. doi: 10.1002/cyto.b.21594. [Epub ahead of print]

PMID:
28985649
12.

A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors.

Sullivan LC, Walpole NG, Farenc C, Pietra G, Sum MJW, Clements CS, Lee EJ, Beddoe T, Falco M, Mingari MC, Moretta L, Gras S, Rossjohn J, Brooks AG.

J Biol Chem. 2017 Dec 22;292(51):21149-21158. doi: 10.1074/jbc.M117.807719. Epub 2017 Sep 25.

PMID:
28972140
13.

Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.

Marras F, Casabianca A, Bozzano F, Ascierto ML, Orlandi C, Di Biagio A, Pontali E, Dentone C, Orofino G, Nicolini L, Taramasso L, Magnani M, Marincola FM, Wang E, Moretta L, De Maria A.

J Virol. 2017 Nov 14;91(23). pii: e00647-17. doi: 10.1128/JVI.00647-17. Print 2017 Dec 1.

14.

CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells.

Ziegler S, Weiss E, Schmitt AL, Schlegel J, Burgert A, Terpitz U, Sauer M, Moretta L, Sivori S, Leonhardt I, Kurzai O, Einsele H, Loeffler J.

Sci Rep. 2017 Jul 21;7(1):6138. doi: 10.1038/s41598-017-06238-4.

15.

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L.

Oncoimmunology. 2017 Apr 20;6(6):e1316439. doi: 10.1080/2162402X.2017.1316439. eCollection 2017.

16.

KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing.

Carlomagno S, Falco M, Bono M, Alicata C, Garbarino L, Mazzocco M, Moretta L, Moretta A, Sivori S.

Front Immunol. 2017 May 26;8:581. doi: 10.3389/fimmu.2017.00581. eCollection 2017.

17.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion.

Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, Rondelli R, Lucarelli B, Brescia LP, Masetti R, Milano GM, Bertaina V, Algeri M, Pinto RM, Strocchio L, Meazza R, Grapulin L, Handgretinger R, Moretta A, Bertaina A, Moretta L.

Blood. 2017 Aug 3;130(5):677-685. doi: 10.1182/blood-2017-04-779769. Epub 2017 Jun 6.

PMID:
28588018
18.

IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Croxatto D, Martini S, Chiossone L, Scordamaglia F, Simonassi CF, Moretta L, Mingari MC, Vacca P.

Oncoimmunology. 2017 Feb 17;6(4):e1293210. doi: 10.1080/2162402X.2017.1293210. eCollection 2017.

19.

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands.

Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017.

20.

HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation.

Nitti M, Piras S, Marinari UM, Moretta L, Pronzato MA, Furfaro AL.

Antioxidants (Basel). 2017 May 5;6(2). pii: E29. doi: 10.3390/antiox6020029. Review.

21.

Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients.

Meazza R, Falco M, Marcenaro S, Loiacono F, Canevali P, Bellora F, Tuberosa C, Locatelli F, Micalizzi C, Moretta A, Mingari MC, Moretta L, Aricò M, Bottino C, Pende D.

Eur J Immunol. 2017 Jun;47(6):1051-1061. doi: 10.1002/eji.201646885. Epub 2017 May 5.

22.

Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.

Bertaina A, Zorzoli A, Petretto A, Barbarito G, Inglese E, Merli P, Lavarello C, Brescia LP, De Angelis B, Tripodi G, Moretta L, Locatelli F, Airoldi I.

Oncoimmunology. 2016 Sep 27;6(2):e1216291. doi: 10.1080/2162402X.2016.1216291. eCollection 2017.

23.

Markers and function of human NK cells in normal and pathological conditions.

Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L.

Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12. Review.

24.

Innate lymphoid cells in normal and disease: An introductory overview.

Moretta L, Locatelli F.

Immunol Lett. 2016 Nov;179:1. doi: 10.1016/j.imlet.2016.07.008. Epub 2016 Jul 9.

PMID:
27400678
25.

Human innate lymphoid cells.

Montaldo E, Vacca P, Vitale C, Moretta F, Locatelli F, Mingari MC, Moretta L.

Immunol Lett. 2016 Nov;179:2-8. doi: 10.1016/j.imlet.2016.01.007. Epub 2016 Feb 1. Review.

PMID:
26844414
26.

Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor.

Pesce S, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2016 Oct 7;7:414. eCollection 2016. Review.

27.

Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.

Manzini C, Venè R, Cossu I, Gualco M, Zupo S, Dono M, Spagnolo F, Queirolo P, Moretta L, Mingari MC, Pietra G.

Oncotarget. 2016 Sep 20;7(38):60858-60871. doi: 10.18632/oncotarget.11504.

28.

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization.

Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E.

J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3. doi: 10.1016/j.jaci.2016.04.025. Epub 2016 May 27.

PMID:
27372564
29.

NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation.

Vacca P, Montaldo E, Croxatto D, Moretta F, Bertaina A, Vitale C, Locatelli F, Mingari MC, Moretta L.

Front Immunol. 2016 May 18;7:188. doi: 10.3389/fimmu.2016.00188. eCollection 2016. Review.

30.

Human NK cells: From surface receptors to clinical applications.

Moretta L, Pietra G, Vacca P, Pende D, Moretta F, Bertaina A, Mingari MC, Locatelli F, Moretta A.

Immunol Lett. 2016 Oct;178:15-9. doi: 10.1016/j.imlet.2016.05.007. Epub 2016 May 13.

PMID:
27185471
31.

Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives.

Li Pira G, Di Cecca S, Montanari M, Moretta L, Manca F.

Blood Rev. 2016 Jul;30(4):297-307. doi: 10.1016/j.blre.2016.03.001. Epub 2016 Mar 16. Review.

PMID:
27066851
32.

Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition.

Saunders PM, Pymm P, Pietra G, Hughes VA, Hitchen C, O'Connor GM, Loiacono F, Widjaja J, Price DA, Falco M, Mingari MC, Moretta L, McVicar DW, Rossjohn J, Brooks AG, Vivian JP.

J Exp Med. 2016 May 2;213(5):791-807. doi: 10.1084/jem.20152023. Epub 2016 Apr 4.

33.

Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.

Furfaro AL, Piras S, Domenicotti C, Fenoglio D, De Luigi A, Salmona M, Moretta L, Marinari UM, Pronzato MA, Traverso N, Nitti M.

PLoS One. 2016 Mar 29;11(3):e0152465. doi: 10.1371/journal.pone.0152465. eCollection 2016.

34.

Mesenchymal Stromal Cells Induce Peculiar Alternatively Activated Macrophages Capable of Dampening Both Innate and Adaptive Immune Responses.

Chiossone L, Conte R, Spaggiari GM, Serra M, Romei C, Bellora F, Becchetti F, Andaloro A, Moretta L, Bottino C.

Stem Cells. 2016 Jul;34(7):1909-21. doi: 10.1002/stem.2369. Epub 2016 Apr 14.

35.

Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1.

Alicata C, Pende D, Meazza R, Canevali P, Loiacono F, Bertaina A, Locatelli F, Nemat-Gorgani N, Guethlein LA, Parham P, Moretta L, Moretta A, Bottino C, Norman PJ, Falco M.

Eur J Immunol. 2016 Jun;46(6):1511-7. doi: 10.1002/eji.201546236.

36.

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.

Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, Moretta L, Moretta A, Bottino C, Castriconi R.

Oncoimmunology. 2015 Jul 15;5(1):e1064578. eCollection 2016.

37.

Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua.

Croxatto D, Micheletti A, Montaldo E, Orecchia P, Loiacono F, Canegallo F, Calzetti F, Fulcheri E, Munari E, Zamò A, Venturini PL, Moretta L, Cassatella MA, Mingari MC, Vacca P.

Mucosal Immunol. 2016 Nov;9(6):1372-1383. doi: 10.1038/mi.2016.10. Epub 2016 Feb 24.

PMID:
26906405
38.

The generation of human innate lymphoid cells is influenced by the source of hematopoietic stem cells and by the use of G-CSF.

Moretta F, Petronelli F, Lucarelli B, Pitisci A, Bertaina A, Locatelli F, Mingari MC, Moretta L, Montaldo E.

Eur J Immunol. 2016 May;46(5):1271-8. doi: 10.1002/eji.201546079. Epub 2016 Feb 19.

39.

The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance.

Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, Pronzato MA, Nitti M.

Oxid Med Cell Longev. 2016;2016:1958174. doi: 10.1155/2016/1958174. Epub 2015 Nov 30. Review.

40.

Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies.

Muccio L, Bertaina A, Falco M, Pende D, Meazza R, Lopez-Botet M, Moretta L, Locatelli F, Moretta A, Della Chiesa M.

Haematologica. 2016 Mar;101(3):371-81. doi: 10.3324/haematol.2015.134155. Epub 2015 Dec 11.

41.

Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?

Della Chiesa M, Sivori S, Carlomagno S, Moretta L, Moretta A.

Front Immunol. 2015 Nov 9;6:573. doi: 10.3389/fimmu.2015.00573. eCollection 2015. Review.

42.

Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment.

Parodi M, Pedrazzi M, Cantoni C, Averna M, Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G, Sivori S, Carlomagno S, Mingari MC, Moretta L, Sparatore B, Vitale M.

Oncoimmunology. 2015 May 29;4(12):e1052353. eCollection 2015 Dec.

43.

Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a.

Grauwet K, Vitale M, De Pelsmaeker S, Jacob T, Laval K, Moretta L, Parodi M, Parolini S, Cantoni C, Favoreel HW.

J Virol. 2015 Nov 18;90(3):1522-33. doi: 10.1128/JVI.02902-15. Print 2016 Feb 1.

44.

'Emergency exit' of bone-marrow-resident CD34(+)DNAM-1(bright)CXCR4(+)-committed lymphoid precursors during chronic infection and inflammation.

Bozzano F, Marras F, Ascierto ML, Cantoni C, Cenderello G, Dentone C, Di Biagio A, Orofino G, Mantia E, Boni S, De Leo P, Picciotto A, Braido F, Antonini F, Wang E, Marincola F, Moretta L, De Maria A.

Nat Commun. 2015 Oct 5;6:8109. doi: 10.1038/ncomms9109.

45.

NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.

Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R, Benelli R, Spaggiari GM, Cantoni C, Campana S, Bonaccorsi I, Morandi B, Truini M, Mingari MC, Moretta L, Ferlazzo G.

Nat Commun. 2015 Sep 23;6:8280. doi: 10.1038/ncomms9280.

PMID:
26395069
46.

Mesenchymal stromal cells and immunity: Introductory overview.

Moretta L, Uccelli A, Pistoia V.

Immunol Lett. 2015 Dec;168(2):127-8. doi: 10.1016/j.imlet.2015.08.010. Epub 2015 Sep 2. No abstract available.

PMID:
26342805
47.

Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry.

Cetica V, Sieni E, Pende D, Danesino C, De Fusco C, Locatelli F, Micalizzi C, Putti MC, Biondi A, Fagioli F, Moretta L, Griffiths GM, Luzzatto L, Aricò M.

J Allergy Clin Immunol. 2016 Jan;137(1):188-196.e4. doi: 10.1016/j.jaci.2015.06.048. Epub 2015 Sep 2.

48.

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation.

Morandi F, Morandi B, Horenstein AL, Chillemi A, Quarona V, Zaccarello G, Carrega P, Ferlazzo G, Mingari MC, Moretta L, Pistoia V, Malavasi F.

Oncotarget. 2015 Sep 22;6(28):25602-18. doi: 10.18632/oncotarget.4693.

49.

Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.

Pietra G, Vitale C, Pende D, Bertaina A, Moretta F, Falco M, Vacca P, Montaldo E, Cantoni C, Mingari MC, Moretta A, Locatelli F, Moretta L.

Cancer Immunol Immunother. 2016 Apr;65(4):465-76. doi: 10.1007/s00262-015-1744-y. Epub 2015 Aug 20. Review.

PMID:
26289090
50.

Haploidentical Haematopoietic Stem Cell Transplantation: Role of NK Cells and Effect of Cytomegalovirus Infections.

Della Chiesa M, Moretta L, Muccio L, Bertaina A, Moretta F, Locatelli F, Moretta A.

Curr Top Microbiol Immunol. 2016;395:209-24. doi: 10.1007/82_2015_450. Review.

PMID:
26160014

Supplemental Content

Loading ...
Support Center